U.S. markets closed

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.7700-0.0500 (-2.75%)
At close: 4:00PM EDT

Ampio Pharmaceuticals, Inc.

373 Inverness Parkway
Suite 200
Englewood, CO 80112
United States
720 437 6500
http://www.ampiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael E. MacalusoFounder, Chairman & CEO457.04kN/A1952
Mr. Daniel G. Stokely CPA, CPACFO, Corp. Sec. & Treasurer419.5kN/A1964
Ms. Holli CherevkaChief Operating Officer288.04kN/A1983
Lane HapkeVP of Manufacturing OperationsN/AN/AN/A
April RamirezClinical Trial Mang.N/AN/AN/A
Laura GoldbergVP of Quality and Regulatory OperationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.

Corporate Governance

Ampio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.